Latest Natera News & Updates

See the latest news and media coverage for Natera. We track all announcements, press releases, and industry mentions in real time, all in one place.

Natera

Cell-free DNA testing company

natera.com

Headquarters: Austin, United States
Founded year: 2004
Company type: Public company
Number of employees: 5,500–10,000

Last updated Today

Latest news about Natera

In short: Natera expanded its leadership in cell-free DNA through strategic acquisitions, clinical trial growth, and a significant victory in a patent trial.

Company announcements

Yesterday Natera

Natera showcases organ health leadership at American Transplant Congress

The company will present 21 studies, including seven oral presentations, on the Prospera test’s utility in transplant monitoring.

June 3 Natera

Natera appoints oncology leaders Lynch and Rubin to board

Dr. Lynch is president of Fred Hutch; Dr. Rubin led KEYTRUDA development at Merck. They join board committees.

May 28 Natera

Natera enrolls first patients in SIGNAL-ER 101 study

The study uses MRD-guided therapy to potentially delay or defer adjuvant CDK4/6 inhibitors in intermediate-risk breast cancer patients, enrolling 725 across 50 U.S. sites.

May 26 Natera

Natera launches enhanced Panorama NIPT with novel deep sequencing technology

The test achieves a 0.5% no-call rate and 100% sensitivity for trisomy 21 at low fetal fraction, validated in a prospective study.

Media coverage

June 17 Stock Titan

Natera, CytoDyn join on ctDNA data in colon cancer | NTRA Stock News

Real-world data from over 2M plasma timepoints will support ctDNA and molecular response analysis in CytoDyn’s CLOVER mCRC trial with leronlimab.

June 16 Investing.com

Natera executive chairman sells $21.4 million in shares By Investing.com

Matthew Rabinowitz, Executive Chairman of Natera, Inc. (NASDAQ:NTRA), sold a total of 100,000 shares of common stock for approximately $21.4 million through multiple transactions on...

June 4 Investing.com

Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com

The sales were executed under a Rule 10b5-1 trading plan, which Mr. Chapman adopted on December 11, 2023, and subsequently amended on December 2, 2024...

June 3 Law360

IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360 UK

A proposed class of in vitro fertilization patients are suing Natera Inc. in California federal court, alleging that it falsely advertised the efficacy and importance...

Never miss news about Natera

Track Natera and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Natera competitors & trending companies

Browse news for competitors to Natera and other trending companies.